Get on top of gout with a fresh look at treatment options

AbstractManaging increasingly prevalent gout, which stems from hyperuricaemia, is not easy. Flare management and long-term serum urate-lowering (ULT) therapy, largely with xanthine oxidase inhibitors (XOIs) or uric acid transporter 1 inhibitors (URAT1Is), are core strategies, but robust comparative trials in these agents are limited. Several are associated, sometimes undeservedly, with adverse drug events. Pipeline URAT1Is report 60 –70% decreases in serum urate, to<  5 mg/dL in most patients. These URAT1Is, plus new XOIs, combination regimens, immunosuppressant adjuncts for intravenous uricases and uricosuric comorbidity medications may all enable simpler, faster, effective and tolerable gout therapy.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research